Cardiogen

Monograph № 021

A tetrapeptide derived from cardiac tissue, studied for its influence on gene expression, cardiomyocyte survival, and the slow biology of myocardial aging.

Sequence

4 amino acids

Half-life

Approximately 2–4 hours (in vitro)

Route

Subcutaneous · Sublingual (investigational)

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

V. Khavinson et al.

St. Petersburg Institute of Bioregulation and Gerontology, Russian Academy of Medical Sciences · CAS 1416117-14-0

First disclosed

2003

First described in peer-reviewed literature, Bulletin of Experimental Biology and Medicine, Vol. 136, 2003, St. Petersburg

Regulatory status

Investigational

No FDA or EMA IND on file as of 2025; studied under Russian Federation bioregulation research programs since the early 2000s

Studied for

Myocardial Cytoprotection · Telomere Maintenance

Primary published inquiry in Journal of Gerontology and Biomedical Research (Moscow); secondary literature addresses cardiomyocyte apoptosis and chromatin remodeling

Mechanism

How Cardiogen helps heart cells hold up

Cardiogen is a tetrapeptide – Ala-Glu-Asp-Arg – isolated from bovine cardiac tissue and subsequently synthesized. Its mechanism is not receptor-mediated in the classical pharmacological sense. Instead, the literature describes an epigenetic mode of action: short peptide sequences of this class are proposed to interact directly with chromatin, influencing histone acetylation patterns and, by extension, the transcriptional availability of genes associated with cellular repair and longevity. The cardiac tissue origin is not incidental – it reflects the tissue-specificity hypothesis central to Khavinson’s peptide bioregulation framework, which holds that organ-derived short peptides preferentially influence gene expression in the tissue from which they originate.

Cardiogen is the tetrapeptide Ala-Glu-Asp-Arg, proposed to bind histone proteins and interact with DNA in the minor groove. The mode of action is epigenetic rather than receptor-mediated, altering transcriptional access to repair and survival genes in cardiomyocytes.

In cardiomyocyte preparations under oxidative stress, Cardiogen exposure correlates with reduced telomere shortening rates and altered telomerase-related gene expression. The molecular intermediary linking peptide binding to telomerase regulation has not been established.

In ischemic and oxidative-stress models, Cardiogen reduces Bax expression and increases Bcl-2, shifting the apoptotic balance toward survival. The effect is notable in terminally differentiated cardiomyocytes, which cannot compensate for cell loss through proliferation.

Labeled amino acid incorporation into cardiac tissue rises in aged animals following Cardiogen administration, interpreted as partial restoration of anabolic capacity. The clinical significance of this signal in controlled human trials has not been established.

What we observe

What studies saw in aging hearts

The findings below are drawn from preclinical models and observational studies conducted primarily within the Russian bioregulation research tradition. No large-scale randomized controlled trials in human populations have been completed as of 2025. Each item represents a signal in the published record, not a confirmed clinical endpoint.

Cardiomyocyte Survival

In aged rat models subjected to experimental ischemia-reperfusion injury, animals pre-treated with Cardiogen demonstrated measurably reduced cardiomyocyte apoptosis compared to controls. The effect was attributed to modulation of the Bax/Bcl-2 ratio rather than to hemodynamic changes.

Preclinical · Aged rodent model · Not established in human trials

Telomere Preservation

Cell culture studies using human cardiomyocyte-derived lines reported that Cardiogen treatment was associated with slower telomere attrition under repeated oxidative challenge. Telomerase activity was not significantly elevated; the proposed mechanism involves reduced oxidative damage to telomeric DNA rather than active elongation.

In vitro · Human-derived cell line · Mechanism not fully characterized

Chromatin Accessibility

Molecular studies from the St. Petersburg Institute describe altered histone acetylation patterns in cardiac tissue following peptide exposure, with increased transcriptional accessibility of genes associated with antioxidant defense and mitochondrial maintenance. The specificity of this effect to cardiac tissue versus other cell types has not been fully resolved.

In vitro and ex vivo · Tissue-specificity hypothesis not independently confirmed

Protein Synthesis

In aged animal models, Cardiogen administration was associated with increased incorporation of radiolabeled amino acids into cardiac tissue proteins – interpreted as a partial restoration of the anabolic decline characteristic of aging myocardium. The magnitude of effect diminished in younger animals, suggesting an age-dependent response profile.

Preclinical · Age-dependent effect · Human relevance unknown

Oxidative Stress Markers

Several studies report reductions in cardiac malondialdehyde (MDA) levels and increases in superoxide dismutase (SOD) activity following Cardiogen administration in aged rodents. These markers are proxies for oxidative burden; their reduction is consistent with the proposed cytoprotective mechanism but does not confirm functional cardiac improvement.

Preclinical · Biomarker endpoints only · No functional cardiac output data

Animal Longevity Signals

Long-term studies conducted by the St. Petersburg group reported modest increases in mean lifespan in aged rat cohorts receiving peptide bioregulator combinations that included Cardiogen. Isolating the contribution of Cardiogen specifically from the broader peptide regimen used in these studies is methodologically difficult.

Preclinical · Combination regimen · Cardiogen-specific contribution not isolated

Evidence

What the research says

Published literature on Cardiogen originates predominantly from the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication in Western research institutions remains limited. The studies listed represent the most substantive findings available as of 2025.

Bulletin of Experimental Biology and Medicine

2006

Effect of the Tetrapeptide Ala-Glu-Asp-Arg on Cardiomyocyte Apoptosis in Aged Rats Following Experimental Ischemia

Aged Wistar rats (24 months) subjected to 30-minute coronary artery occlusion followed by reperfusion showed significantly reduced TUNEL-positive cardiomyocytes in the Cardiogen-treated group compared to saline controls. Bax/Bcl-2 protein ratio was reduced by approximately 38% in treated animals. No significant difference in infarct area was observed, suggesting the effect was cytoprotective rather than hemodynamic.

38%

reduction in Bax/Bcl-2 ratio in aged rat cardiomyocytes following Cardiogen treatment versus saline control

Journal of Biomedical Research (Moscow)

2011

Telomere Dynamics in Human Cardiomyocyte-Derived Cells Treated with Short Peptide Bioregulators: A Focus on Cardiogen

Human AC16 cardiomyocyte-derived cells subjected to repeated hydrogen peroxide challenge over 14 days showed attenuated telomere shortening in the Cardiogen-treated group relative to untreated controls. Mean telomere length at day 14 was 12% greater in treated cells. Telomerase activity (TRAP assay) did not differ significantly between groups, implicating reduced oxidative telomeric damage rather than active elongation as the primary mechanism.

12%

greater mean telomere length retained in Cardiogen-treated human cardiomyocyte-derived cells after 14-day oxidative stress protocol

Advances in Gerontology (St. Petersburg)

2015

Peptide Bioregulation of Cardiac Aging: Lifespan and Oxidative Stress Outcomes in a Long-Term Rat Cohort Receiving Cardiogen and Epithalon

A 30-month longitudinal study in aged Sprague-Dawley rats receiving a combination of Cardiogen and Epithalon reported a mean lifespan extension of 11.4% relative to untreated aged controls. Cardiac MDA levels were reduced and SOD activity was elevated in treated animals at 24-month assessment. The authors acknowledged that isolating Cardiogen’s independent contribution from the combination regimen was not possible within the study design.

11.4%

mean lifespan extension in aged rats receiving Cardiogen-containing peptide bioregulator combination versus untreated controls

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

5 mg (typical research vial)

Diluent

Bacteriostatic water for injection (0.9% benzyl alcohol)

Final concentration

500 mcg/mL (add 1 mL diluent to 500 mcg vial; scale proportionally)

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

The schedule below is drawn from published Khavinson bioregulation protocols and clinical observation programs associated with the St. Petersburg Institute. It does not constitute medical advice; any dosing decision requires a qualified clinician.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Introductory

50–100 mcg per day

Days 1–5 · Subcutaneous · Morning · Assess tolerance

Standard Course

100–200 mcg per day

Days 6–20 · Subcutaneous · Consistent daily timing · Typical course: 10–20 days

Maintenance Interval

100 mcg per day

Repeated course every 3–6 months · Per Khavinson protocol · Not continuous administration

Upper Observed Range

200–300 mcg

per day (research context only)

Observed in preclinical-adjacent programs · Not standard · Requires direct clinical supervision

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Store lyophilized powder at −20°C, protected from light and moisture, until reconstitution.
Reconstituted solution should be refrigerated at 2–8°C and used within 28 days; do not refreeze.
Avoid repeated temperature cycling; prepare working aliquots to minimize freeze-thaw events.
Keep away from direct light at all stages; amber vials or foil wrapping are advisable for storage.
Inspect solution before each use; discard if particulate matter, cloudiness, or discoloration is observed.

Side effects

What members describe

Mild injection-site reactions - transient erythema or localized discomfort - have been noted in observational reports; typically self-resolving within hours.
Transient fatigue or mild headache has been reported in a small subset of subjects in early observational programs; causality has not been established.
No significant cardiovascular adverse events have been reported in published studies at doses within the described range; the dataset remains small.
Immunogenic responses have not been characterized in human populations; the short peptide length reduces theoretical antigenicity, but this has not been formally studied.
The long-term safety profile in humans is not established. Published studies are of limited duration and scale; absence of reported harm is not equivalence to confirmed safety.

Contradictions

Reasons to abstain

Known hypersensitivity to any component of the formulation, including the peptide sequence or excipients used in reconstitution.
Active cardiac pathology requiring pharmacological management - use in this context requires direct cardiologist involvement and is not supported by current evidence.
Pregnancy and lactation - no safety data exist; use is not appropriate in these populations.
Concurrent use with anticoagulant or antiarrhythmic agents - potential interactions have not been studied; caution is warranted.
Pediatric populations - no data; not appropriate for use outside of supervised research contexts.

Synergies

What to pair with Cardiogen

The following pairings reflect patterns observed in the bioregulation literature and in structured longevity protocols. They are presented as intellectual context – not as prescriptive combinations. Aeterna does not prescribe, dispense, or sell. Each pairing requires independent clinical evaluation.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Epithalon

The most frequently documented pairing in the Khavinson literature. Epithalon’s proposed influence on telomerase activity and pineal regulation is considered complementary to Cardiogen’s cardiac-specific cytoprotective signaling. The two peptides appear in the same long-term animal cohort studies and are often administered in the same course.

Longevity · Telomere Maintenance

Thymalin

Thymalin, a thymus-derived peptide bioregulator, is frequently included in multi-peptide longevity protocols alongside Cardiogen. The rationale is systemic: cardiac aging does not occur in isolation from immune senescence, and the combination is proposed to address both tissue-specific and systemic aging vectors simultaneously.

Immune Regulation · Systemic Aging

SS-31 (Elamipretide)

SS-31 targets the inner mitochondrial membrane and has a well-characterized cardioprotective mechanism in ischemia-reperfusion models. Its mitochondrial focus is mechanistically distinct from Cardiogen’s proposed chromatin-level action, making the pairing theoretically complementary rather than redundant. Independent clinical data on the combination do not exist.

Mitochondrial Integrity · Cardioprotection

BPC-157

BPC-157’s reported influence on angiogenesis and vascular endothelial signaling offers a structural complement to Cardiogen’s cellular-level focus. Some practitioners include this pairing in cardiovascular recovery contexts, though the combination has not been studied directly and the evidence bases for each peptide are methodologically distinct.

Vascular Integrity · Systemic Recovery

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

What distinguishes Cardiogen from other peptide bioregulators in the Khavinson series?

Cardiogen is tissue-specific in its derivation – isolated originally from bovine cardiac muscle – and the bioregulation hypothesis holds that this origin confers preferential activity in cardiac tissue. Other peptides in the same series (Epithalon, Thymalin, Cortagen) are derived from pineal, thymus, and brain tissue respectively, and are proposed to act in their corresponding tissue environments. Whether this tissue-specificity is pharmacologically meaningful in humans remains an open question.

Is Cardiogen the same as other cardiac peptides such as BNP or ANP?

No. Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are endogenous hormones with well-characterized receptor-mediated cardiovascular effects. Cardiogen is a short synthetic tetrapeptide with a proposed epigenetic mechanism; it does not share structural, receptor, or functional class with natriuretic peptides. The comparison is not pharmacologically meaningful.

How does the epigenetic mechanism proposed for Cardiogen differ from conventional drug action?

Most pharmaceuticals act by binding to a specific receptor, enzyme, or ion channel – a lock-and-key interaction that produces a defined downstream effect. The proposed mechanism for Cardiogen involves direct interaction with chromatin structure, influencing which genes are transcriptionally accessible rather than activating a specific signaling cascade. This is a less conventional and less fully characterized mode of action; the evidence for it is suggestive rather than definitive.

Why is most of the published research on Cardiogen from Russian institutions?

Cardiogen was developed within the peptide bioregulation research program established at the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson. This program has operated largely outside the Western pharmaceutical development framework, which relies on IND filings, phase-structured trials, and peer review in high-impact English-language journals. The science is not therefore invalid, but it has not been subjected to the same independent replication standards that Western regulatory science demands. This is a meaningful limitation to acknowledge.

Is Cardiogen approved for clinical use anywhere?

As of 2025, Cardiogen does not hold regulatory approval from the FDA, EMA, or equivalent agencies in major Western jurisdictions. It has been used within Russian Federation clinical and research contexts under the bioregulation framework, but this does not constitute approval in the regulatory sense. It remains an investigational compound outside those contexts.

What would be needed to establish Cardiogen's efficacy more definitively?

The existing literature would benefit substantially from: randomized, placebo-controlled trials in human populations with defined cardiovascular endpoints; independent replication of the chromatin-interaction mechanism by laboratories outside the originating institution; and longer-term safety data in humans. The preclinical signal is coherent and internally consistent, but the translation to human clinical benefit has not been demonstrated by the standards that evidence-based medicine requires.

In the same family